Skip to main content
. 2022 Jul 6;12:943407. doi: 10.3389/fcimb.2022.943407

Figure 2.

Figure 2

Details of SARS-CoV-2 vaccination for selected patients. (A) Proportions of heterogeneous vaccination (HeV) and homologous vaccination (HoV). (B) Comparison of the time to target cycle threshold value (TtCT) between HeV and HoV. (C) Proportions of different vaccines for homologous vaccination. (D) Comparison of TtCT among different vaccines for homologous vaccination. (E) Comparison of TtCT between the two-dose primary vaccination and the three-dose booster vaccination of CoronaVac. (F) Comparison of TtCT between two-dose primary vaccination and three-dose booster vaccination of Sinopharm BBIBP-CorV.